AUG 11, 2026 · JOURNAL ARTICLE
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis
International Journal of Clinical Oncology
Rigorous phase 3 pooled analysis demonstrating a clinically meaningful OS benefit (HR 0.46) with durable 5-year survival gains in a population with high unmet need and poor prognosis, though sample size in the Japanese subgroup is modest.
Reported
Overall survival (median)41.0 vs 15.2 months
Overall survival hazard ratio0.46
Overall survival HR 95% CI0.27–0.78